Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated recombinant human erythropoietin
- Development stage
- Preclinical
- Lead developer
- Xiamen Tebao Biological Engineering
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
Pegylated recombinant human erythropoietin is a **recombinant protein** engineered by attaching polyethylene glycol (PEG) chains to human erythropoietin, which increases the molecule's size and prolongs its half-life in circulation. It acts by binding to the **erythropoietin receptor** on erythroid progenitor cells in the bone marrow, stimulating red blood cell production and preventing apoptosis of these cells. The longer-acting profile of PEGylated rHuEPO allows for reduced dosing frequency compared to standard recombinant erythropoietin. It is under investigation as a treatment for anemia in disorders such as chronic kidney disease and for reducing transfusion needs in other diseases characterized by impaired red blood cell production. PEGylation confers improved pharmacokinetics, reduced renal clearance, and high bioavailability. The drug distributes primarily to plasma, blood, bone marrow, and the injection site, with urinary elimination as the principal excretion route[1][3].
- Other names
- PEG-rHuEPOPEGylated rHuEPOlarge-rHuEPO
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on pegylated recombinant human erythropoietin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated recombinant human erythropoietin.